English Українська
  • Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

    •
    Article
    World of Medicine and Biology / №2(60), 2017 / COMPARATIVE ANALYSIS OF CLINICAL EFFICACY TAFLUPROST IN THE TREATMENT OF VARIOUS FORMS OF OPEN-ANGLE GLAUCOMA
    Ibadova N. T.

    COMPARATIVE ANALYSIS OF CLINICAL EFFICACY TAFLUPROST IN THE TREATMENT OF VARIOUS FORMS OF OPEN-ANGLE GLAUCOMA

    About the author: Ibadova N. T.
    Heading CLINICAL MEDICINE
    Type of article Scentific article
    Annotation In this prospective cohort study included 65 patients (118 eyes) with diagnosed primary open-angle glaucoma with intraocular pressure (IOP) of 40 mm Hg. article and with the absence of pathology of the macular zone, which was assigned to prostaglandin therapy in the form of a single instillation of the drug Taflotan® no preservative. The mean reduction of IOP from baseline during the observation period of 1 month after the appointment Taflotan in groups of POAG and PEG was 33.8% and 32.3%, respectively. Thus, in the eyes of POAG with higher IOP at the last control was lower than in eyes with PEG (p < 0.01). The average follow-up period was 12 months. Mean baseline IOP in patients with POAG and PEG was 31,7 ± 0,6 mm Hg. article and 32.5 ± 0,7 mm Hg. art., respectively. In the eyes of POAG with higher IOP at the last control was lower than in eyes with PEG (p < 0.01). The average observation time was 12 months. Travoprost has a pronounced clinical efficacy in various forms of open-angle glaucoma with a minimum frequency of local side effects. However, travoprost monotherapy in POAG leads to a greater decrease in IOP than the PEG during the observation period of 12 months.
    Tags intraocular pressure, glaucoma, prostaglandins, tafluprost
    Bibliography
    • Demirel S. Toxic-inflammatory effects of prostaglandin analogs on the ocular surface./ S. Demirel, S. Doganay, Gurses I. et al. // Ocul Immunol Inflamm., 2013, v.21(1), p.13-8.
    • Doucette L.P. Prostaglandins in the eye: Function, expression, and roles in glaucoma./ L. P. Doucette, M. A. Walter // Ophthalmic Genet. 2017 Mar-Apr;38(2):108-116. doi: 10.3109/13816810.2016.1164193. Epub 2016 Apr 12.
    • European Glaucoma Society, Terminology and Guidelines for Glaucoma, 4th edition, 2014, Chapter 3, p.122-143.
    • Franca J. R. Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation. / J. R. Franca, G. Foureaux, L. L. Fuscaldi, et al. // PLoS One. 2014 Apr 30;9(4):e95461.
    • Hodapp E. Clinical Decisions in Glaucoma. / E. Hodapp, R. K. Parrish, D. R. Anderson //St Louis: Mosby; 1993:53–61.
    • Hommer A. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. / A. Hommer, O. Mohammed Ramez, M. Burchert et al. //Curr Med Res Opin. 2010 Aug; 26(8):1905-13.
    • Jessen B.A. Safety assessment of subconjunctivally implanted devices containing latanoprost in Dutch-belted rabbits./ B. A. Jessen, M. H. Shiue, H. Kaur, et al.  // J Ocul Pharmacol Ther., 2013, v.29(6), p.574-85.
    • Johnson T. V. Aqueous humor dynamics in exfoliation syndrome./ T. V. Johnson, S. Fan, C. B. Camras, C. B. Toris // Arch. Ophthalmol., 2008, v.126, p.914–920.
    • Kashiwagi K. Development of latanoprost-loaded biodegradable nanosheet as a new drug delivery system for glaucoma./ K.Kashiwagi, K.Ito, H.Haniuda, S.Ohtsubo, S.Takeoka  // Invest Ophthalmol Vis Sci., 2013, v.19; 54(8), p.5629-37.
    • Kim E.J. In vitro effects of preservative-free and preserved prostaglandin analogs on primary cultured human conjunctival fibroblast cells./ E. J. Kim, Y. H. Kim, S. H .Kang et al.  // Korean J Ophthalmol., 2013, v. 27(6), p.446-53.
    • Konstas A.G. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension./ A.G.Konstas, L.Quaranta, A.Katsanos, et al.  // Br J Ophthalmol., 2013, v.97(12), p.1510-5.
    • Kremmer S. Influence of latanoprost on retinal microcirculation in glaucoma. / S. Kremmer, M. Iliadou, G. Anastassiou, et al. //Open Ophthalmol J. 2014 Oct 3;8:60-6.
    • Li J. Meta-analysis of randomized controlled trials comparing latanoprost with other glaucoma medications in chronic angle-closure glaucoma. / J.Li, X.Lin, M.Yu, J.Li, X.Lin, M.Yu //Eur J Ophthalmol. 2015 Jan-Feb; 25 (1):18-26.
    • Maruyama K. Incidence of deepening of upper eyelid sulcus a fter topical use of tafluprost ophthalmic solution in Japanese patients./ K.Maruyama, A.Tsuchisaka, J.Sakamoto, S.Shirato, H.Goto  // Clin Ophthalmol., 2013, v.7, p.1441-1446.
    • Mishra D. Comparing the efficacy of latanoprost (0.005%), bimatoprost (0.03%), travoprost (0.004%), and timolol (0.5%) in the treatment of primary open angle glaucoma. / D.Mishra, B.P.Sinha, M.S. Kumar // Korean J Ophthalmol. 2014 Oct;28(5):399-407.
    •  Nilsson S.F.E. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. / S.F.E.Nilsson, E.Drecoll, E.Lu¨ tjen-Drecoll, et al.  // Invest. Ophthalmol. Vis. Sci., 2006, v.47, p. 4042–4049.
    • Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle: a study on cultured cells and tissue sections./ A. Ocklind // Exp. Eye Res., 1998, v.67, p.179–191.
    • Petrov SIu. Tafluprost--a novel prostaglandin F2alpha analogue. / SIu Petrov.//Vestn Oftalmol. 2014 Sep-Oct;130(5):85-95.
    •   Qasımov E.M. Birincili açıq bucaqlı qlaukomanın müxtəlif formalarının müalicəsində uveoskleral axının artırılmasının rolu (ədəbiyyat icmalı)./ E.M.Qasımov, N.T.Ibadova // Oftalmologiya Elmi-Praktik Jurnal 2014: 2 (15). S. 91-97.
    • Sakurai M. Association between genetic polymorphisms of the prostaglandin F2α receptor gene, and response to latanoprost in patients with glaucoma and ocular hypertension./ M. Sakurai, T. Higashide, S. Ohkubo, et al. // Br J Ophthalmol., 2014 v.98(4), p.469-73.
    • Swymer C. Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension. / C. Swymer, M.W. Neville //Ann Pharmacother. 2012 Nov;46(11):1506-10.
    • Tan J. Latanoprost-induced prostaglandin-associated periorbitopathy./ J.Tan, S. Berke  // Optom Vis Sci., 2013, v.90(9), p.e245-7; discussion 1029.
    • Uusitalo H. Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical./ H. Uusitalo, E .Egorov, K. Kaarniranta [et al.] // Clin Ophthalmol. 2016 Mar 15;10: 445-54.
    Publication of the article «World of Medicine and Biology» №2(60), 2017 year, 059-063 pages, index UDK 615: 617.7-007.681